Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
Ticker SymbolETON
Company nameEton Pharmaceuticals Inc
IPO dateNov 09, 2018
CEOMr. Sean E. Brynjelsen
Number of employees31
Security typeOrdinary Share
Fiscal year-endNov 09
Address21925 W Field Pkwy Ste 235
CityDEER PARK
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code60010-7278
Phone18477877361
Websitehttps://etonpharma.com/
Ticker SymbolETON
IPO dateNov 09, 2018
CEOMr. Sean E. Brynjelsen
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data